These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 1126604

  • 21. Risk-benefit equation for erythromycin estolate.
    LeBel M.
    Am J Hosp Pharm; 1980 Feb; 37(2):176, 180. PubMed ID: 7361788
    [No Abstract] [Full Text] [Related]

  • 22. Erythromycin propionate and estolate.
    Farre M.
    Lancet; 1988 Jul 02; 2(8601):45. PubMed ID: 2898648
    [No Abstract] [Full Text] [Related]

  • 23. Erythromycin estolate hepatotoxicity.
    Lloyd-Still JD, Sherman JO, Boggs J, Demers LM.
    Am J Dis Child; 1978 Mar 02; 132(3):320. PubMed ID: 629252
    [No Abstract] [Full Text] [Related]

  • 24. Ilosone update.
    Culp ER.
    Am Fam Physician; 1980 Apr 02; 21(4):23. PubMed ID: 7377065
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Hepatotoxicity of erythromycin estolate during pregnancy.
    McCormack WM, George H, Donner A, Kodgis LF, Alpert S, Lowe EW, Kass EH.
    Antimicrob Agents Chemother; 1977 Nov 02; 12(5):630-5. PubMed ID: 21610
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Hepatotoxicity of erythromycin derivatives.
    Pessayre D, Benhamou JP.
    Br Med J; 1979 May 19; 1(6174):1357. PubMed ID: 445081
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Jaundice, liver ultrastructure, and congenital pyloric stenosis. A study in infants.
    Levine G, Favara BE, Mierau G, Bailey WC.
    Arch Pathol; 1973 Apr 19; 95(4):267-70. PubMed ID: 4696050
    [No Abstract] [Full Text] [Related]

  • 35. [On the article of J. Buchanec and V. Kdrajnák: Lesions of the liver during therapy with erythromycin in 3 children].
    Rouzica M, Filipová K.
    Cesk Pediatr; 1975 Jan 19; 30(1-2):71. PubMed ID: 1132045
    [No Abstract] [Full Text] [Related]

  • 36. Case study: Drug interference in clinical chemistry.
    Hansen JL, Swanson LN.
    Am J Med Technol; 1981 Mar 19; 47(3):189-91. PubMed ID: 7223765
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Therapeutic doses of erythromycin esteolate is not cholestatic in rats in vivo.
    Fiebiger I, Anwer MS, Hegner D.
    Naunyn Schmiedebergs Arch Pharmacol; 1983 May 19; 322(4):295-7. PubMed ID: 6866136
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A prospective study on the incidence of liver function abnormalities in children receiving erythromycin estolate, erythromycin ethylsuccinate or penicillin V for treatment of pneumonia.
    Ginsburg CM.
    Pediatr Infect Dis; 1986 May 19; 5(1):151-3. PubMed ID: 3080735
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.